# TLX1

## Overview
TLX1, or T cell leukemia homeobox 1, is a gene that encodes a transcription factor involved in the regulation of gene expression during T-cell development and spleen morphogenesis. The protein product of TLX1 is characterized by a homeobox domain, which facilitates its role as a DNA-binding transcription factor. This domain is integral to the protein's function in modulating retinoic acid (RA) signaling pathways, crucial for the proliferation and differentiation of spleen mesenchymal cells (Lenti2016Transcription). TLX1 is implicated in the pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL), where its overexpression is associated with differentiation arrest and leukemogenesis (Bardelli2021TCell). The protein interacts with various signaling pathways, including NOTCH1 and STAT5, to influence oncogenic processes (Vanden2018Cooperative). Additionally, TLX1's role in congenital asplenia highlights its importance in normal spleen development (Lenti2016Transcription).

## Structure
TLX1 (T cell leukemia homeobox 1) is a transcription factor characterized by the presence of a homeobox domain, which is a DNA-binding motif. This domain typically consists of 60 amino acids forming a helix-turn-helix structure, a common feature in proteins that interact with DNA. The homeobox domain is crucial for the protein's role in regulating gene expression during T-cell development.

The protein may undergo post-translational modifications, such as phosphorylation, which can influence its activity and interactions. These modifications are important for the regulation of TLX1's function in cellular processes.

TLX1 has the ability to form dimers, indicating that it possesses a quaternary structure. Dimerization is often essential for the biological activity of transcription factors, as it can affect their DNA-binding affinity and specificity. The ability to form dimers suggests that TLX1 may interact with other proteins or itself to exert its function in the cell.

Overall, the structural features of TLX1, including its homeobox domain and potential for post-translational modifications and dimerization, are integral to its role in T-cell development and function.

## Function
The TLX1 gene, also known as T-cell leukemia homeobox 1, is a transcription factor that plays a crucial role in spleen development by regulating retinoic acid (RA) signaling. It is essential for the proper proliferation and differentiation of spleen mesenchymal cells, ensuring normal spleen morphogenesis. TLX1 controls excessive RA signaling, which is vital for the proliferation of mesenchymal precursors and the formation of the splenic anlage. In the absence of TLX1, there is increased RA activity, leading to premature differentiation and growth arrest in the spleen (Lenti2016Transcription).

TLX1 functions by binding to DNA through the AP-1 motif, affecting the expression of genes involved in RA signaling, such as Cyp26b1, Rara, and Rxra. It interacts with other transcription factors like JDP2 to repress RA-induced differentiation, highlighting its role in directly regulating RA target genes (Lenti2016Transcription). TLX1 is primarily active in the nucleus, where it modulates the transcription of target genes, influencing cell fate and growth (Riz2009Transcriptional). This regulation is crucial for maintaining the balance of RA signaling, preventing premature cellular differentiation, and ensuring proper spleen development (Lenti2016Transcription).

## Clinical Significance
The TLX1 gene is clinically significant due to its role in T-cell acute lymphoblastic leukemia (T-ALL). Overexpression of TLX1 is linked to a subgroup of T-ALL characterized by differentiation arrest at the cortical stage of T-cell development, often associated with CD1a expression. This subgroup frequently exhibits altered cell cycle processes and mitotic defects, leading to aneuploidy. TLX1-positive T-ALL cases commonly have NOTCH1 mutations and deletions or mutations in BCL11B and PTPN2, which contribute to leukemogenesis (Riz2010TLX1; Bardelli2021TCell).

TLX1's inappropriate expression, often due to chromosomal translocations, is implicated in approximately 30% of adult and 8% of childhood T-ALL cases. It cooperates with NOTCH1 mutations to modulate the NOTCH-TLE regulatory network and enhance MYC protein levels, promoting the growth and survival of T-ALL cells (Riz2010TLX1). Inhibition of NOTCH signaling has shown potential in treating TLX1-positive T-ALL, although the effect is often transient, suggesting the need for combination therapies (Rakowski2011Transient).

TLX1 is also involved in congenital asplenia due to its role in regulating retinoic acid signaling, which is crucial for spleen development. Mutations or expression alterations in TLX1 can lead to disrupted RA signaling pathways, contributing to spleen development disorders (Lenti2016Transcription).

## Interactions
TLX1, a transcription factor, engages in several interactions with other proteins and nucleic acids, playing a significant role in transcriptional regulation. It interacts with Groucho/TLE corepressors, such as TLE1, through an Eh1-like motif, which is crucial for its transcriptional activation and repression functions. This interaction is essential for the activation of genes like Aldh1a1 and Fhl1 in NIH3T3 cells, and mutations in TLX1 that disrupt this interaction lead to reduced gene activation (Riz2009Transcriptional).

In the context of T-cell acute lymphoblastic leukemia (T-ALL), TLX1 interacts with the NOTCH1 signaling pathway, forming a regulatory network that includes MYC. This network is vital for the growth and survival of TLX1-positive T-ALL cells, as TLX1 modulates the NOTCH-TLE regulatory network, enhancing MYC protein levels posttranscriptionally (Riz2010TLX1).

TLX1 also cooperates with STAT5, another transcription factor, in T-ALL. They co-bind to enhancer regions, leading to the activation of oncogenic enhancers and genes such as MYC and BCL2. This interaction is significant in the development of NUP214-ABL1/TLX1-positive T-ALL, where TLX1 and STAT5 binding correlates with increased chromatin accessibility and enhancer-mediated gene expression changes (Vanden2018Cooperative).


## References


[1. (Riz2010TLX1) Irene Riz, Teresa S Hawley, Truong V Luu, Norman H Lee, and Robert G Hawley. Tlx1 and notch coregulate transcription in t cell acute lymphoblastic leukemia cells. Molecular Cancer, July 2010. URL: http://dx.doi.org/10.1186/1476-4598-9-181, doi:10.1186/1476-4598-9-181. This article has 22 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1186/1476-4598-9-181)

[2. (Lenti2016Transcription) Elisa Lenti, Diego Farinello, Kazunari K. Yokoyama, Dmitry Penkov, Laura Castagnaro, Giovanni Lavorgna, Kenly Wuputra, Lisa L. Sandell, Naomi E. Butler Tjaden, Francesca Bernassola, Nicoletta Caridi, Anna De Antoni, Michael Wagner, Katja Kozinc, Karen Niederreither, Francesco Blasi, Diego Pasini, Gregor Majdic, Giovanni Tonon, Paul A. Trainor, and Andrea Brendolan. Transcription factor tlx1 controls retinoic acid signaling to ensure spleen development. Journal of Clinical Investigation, 126(7):2452–2464, May 2016. URL: http://dx.doi.org/10.1172/jci82956, doi:10.1172/jci82956. This article has 31 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci82956)

[3. (Rakowski2011Transient) Lesley A. Rakowski, Erica A. Lehotzky, and Mark Y. Chiang. Transient responses to notch and tlx1/hox11 inhibition in t-cell acute lymphoblastic leukemia/lymphoma. PLoS ONE, 6(2):e16761, February 2011. URL: http://dx.doi.org/10.1371/journal.pone.0016761, doi:10.1371/journal.pone.0016761. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0016761)

[4. (Bardelli2021TCell) Valentina Bardelli, Silvia Arniani, Valentina Pierini, Danika Di Giacomo, Tiziana Pierini, Paolo Gorello, Cristina Mecucci, and Roberta La Starza. T-cell acute lymphoblastic leukemia: biomarkers and their clinical usefulness. Genes, 12(8):1118, July 2021. URL: http://dx.doi.org/10.3390/genes12081118, doi:10.3390/genes12081118. This article has 43 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/genes12081118)

[5. (Riz2009Transcriptional) Irene Riz, Hyo Jung Lee, Kristin K. Baxter, Reza Behnam, Teresa S. Hawley, and Robert G. Hawley. Transcriptional activation by tlx1/hox11 involves gro/tle corepressors. Biochemical and Biophysical Research Communications, 380(2):361–365, March 2009. URL: http://dx.doi.org/10.1016/j.bbrc.2009.01.099, doi:10.1016/j.bbrc.2009.01.099. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2009.01.099)

[6. (Vanden2018Cooperative) Marlies Vanden Bempt, Sofie Demeyer, Michaël Broux, Jolien De Bie, Simon Bornschein, Nicole Mentens, Roel Vandepoel, Ellen Geerdens, Enrico Radaelli, Beat C. Bornhauser, Andreas E. Kulozik, Jules P. Meijerink, Jean-Pierre Bourquin, Charles E. de Bock, and Jan Cools. Cooperative enhancer activation by tlx1 and stat5 drives development of nup214-abl1/tlx1-positive t cell acute lymphoblastic leukemia. Cancer Cell, 34(2):271-285.e7, August 2018. URL: http://dx.doi.org/10.1016/j.ccell.2018.07.007, doi:10.1016/j.ccell.2018.07.007. This article has 43 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.ccell.2018.07.007)